Strategic Acquisition Resolution Bioscience was acquired by Exact Sciences in 2023, signaling potential access to larger customer networks, cross-sell opportunities for companion diagnostics, and expanded distribution channels through the parent company.

Clinical Adoption Recent achievements include Breakthrough Device Designation for the HRD assay, highlighting regulatory credibility and a pathway to reimbursement and broader physician adoption that can be leveraged to upsell additional liquid biopsy panels.

Partnership Potential Historical collaborations with Mirati Therapeutics and LabCorp illustrate a proven model for co-development and broadened clinical utility, suggesting opportunities to partner with oncology drug developers and large reference laboratories.

Product Portfolio A portfolio of over fifty focused panels and ongoing companion diagnostics efforts indicate multiple entry points for hospital systems and clinics seeking comprehensive liquid biopsy solutions for treatment selection and monitoring.

Market Positioning Operating in the high-growth liquid biopsy space with modest current revenue, there is a clear path to scale via Exact Sciences’ resources, network, and potential multi-institution contracts targeting cancer care improvements.